Rejuvenate Bio has received a $4M grant from the California Institute for Regenerative Medicine (CIRM) to complete IND-enabling activities for the development of RJB-0402, a novel gene therapy for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM).

California Institute For Regenerative Medicine (Cirm)

Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases.

rejuvenatebio.com

Rejuvenate Bio Receives $4M Grant from California Institute for Regenerative Medicine (CIRM) for RJB-0402 Development

Investors

Description

Company Information

Related People

Funding Insights

Rejuvenate Bio Receives $4M Grant from California Institute for Regenerative Medicine (CIRM) for RJB-0402 Development

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information